FDA Cites Indian Drugmaker for Sterility, Testing Issues

Drug Industry Daily
A A
The FDA flagged a Shilpa Medicare facility in Telangana, India for numerous violations including noncompliant labeling, sterility procedures and testing methods.

To View This Article:

Login

Subscribe To Drug Industry Daily